

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

September 29, 2021
Date of Report (Date of Earliest Event Reported)



The Chemours Company
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
Of Incorporation)

001-36794
(Commission
File Number)

46-4845564
(I.R.S. Employer
Identification No.)

1007 Market Street
Wilmington, Delaware, 19801
(Address of principal executive offices)

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Trading Symbol(s)</u>	<u>Name of Exchange on Which Registered</u>
Common Stock (\$.01 par value)	CC	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 29, 2021, The Chemours Company (“Chemours”) announced certain appointments within its finance leadership team as further described below.

***Appointment of Camela T. Wisel
Vice President, Chief Accounting Officer and Controller***

Camela T. Wisel, age 46, has been appointed to the position of Vice President, Chief Accounting Officer and Controller. Ms. Wisel will serve as principal accounting officer for purposes of Chemours’ filings with the Securities and Exchange Commission. Prior to this appointment, Ms. Wisel served as Chemours’ Vice President and Treasurer since September 2020. Before that, she held various positions of increasing responsibilities in Controllershship and Treasury since joining Chemours in April 2015. Prior to joining Chemours, Ms. Wisel was Senior Manager in External Reporting and Accounting Policy at Trinseo. Prior to Trinseo, Ms. Wisel was a Senior Manager with PricewaterhouseCoopers LLP (“PwC”) with over ten years of experience serving in PwC’s Assurance Services in both the Philadelphia and Singapore offices.

In connection with her appointment, Ms. Wisel will receive an annual base salary of \$312,500 and be eligible for a target Annual Incentive Plan (AIP) award of 50% of base salary and a target Long Term Incentive Plan (LTIP) award of \$300,000. She will participate in the Chemours’ Senior Executive Severance Plan and in other benefit plans offered to Chemours’ officers.

There are no arrangements or understandings between Ms. Wisel and any other persons in connection with her appointment. Ms. Wisel does not have any family relationships with any executive officer or director of Chemours and she is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

***Appointment of Matthew S. Abbott
Vice President, Digital and Analytics Platforms Leader***

Matthew S. Abbott, age 45, has been appointed to the position of Vice President, Digital and Analytics Platforms Leader. Prior to this appointment, Mr. Abbott served as Chemours’ Vice President, Chief Accounting Officer and Controller since August 2019 and Vice President and Chief Audit Executive since January 2017. Prior to joining Chemours, Mr. Abbott was a Partner at PwC for five years, with nearly twenty total years of experience serving PwC’s industrial products and technology clients.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CHEMOURS COMPANY

By: /s/ Sameer Ralhan
Sameer Ralhan
Senior Vice President, Chief Financial Officer

Date: September 29, 2021